Energy consumption in organisms should be finely regulated to spare resources. The vast majority of eukaryotic cells perform oxidative phosphorylation (OXPHOS), which uses the energy generated by mitochondrial oxidation to produce adenosine triphosphate (ATP). This metabolic pathway is highly efficient in releasing energy but it produces reactive oxygen species (ROS) as a byproduct. ROS are involved in normal cell signaling and homeostasis. However, under stress conditions levels may rapidly increase resulting in cell damage, a process known as oxidative stress. Hence, cells using mitochondria as first energy source must regulate ROS levels. Logically, ROS and mitochondria are functionally linked in several ways. First, ROS in the short-term regulate mitochondrial morphology and function via non-transcriptional pathways 1 . Second, ROS lead to Kelch-like ECH-associated protein 1 (KEAP-1) degradation, thereby activating nuclear factor (erythroid-derived 2)-like 2 (NFE2L2 or NRF2) 2,3 , which regulates expression of mitochondrial genes 4 . In addition, NRF2 controls ROS production by mitochondria 5 and mitochondrial function 6, 7 . NRF2 arguably mediates the strongest anti-oxidant cellular response by binding to anti-oxidant response elements (ARE) in gene promoters and, consequently, regulates oxidative stress 2, 3 . On the other hand, mitochondrial activity induced by acute exercise promotes Ref1/Nrf2 signaling and increases mitochondrial antioxidant activity and capacity in myocardial and skeletal muscle 8, 9 . Remarkably, restraining OXPHOS in vivo in the liver strongly decreases Nrf2 levels 10 . Moreover, tumor cells forced to perform
Oxidative phosphorylation (OXPHOS) generates ROS as a byproduct of mitochondrial complex I activity. ROS-detoxifying enzymes are made available through the activation of their antioxidant response elements (ARE) in their gene promoters. NRF2 binds to AREs and induces this anti-oxidant response. We show that cells from multiple origins performing OXPHOS induced NRF2 expression and
Energy consumption in organisms should be finely regulated to spare resources. The vast majority of eukaryotic cells perform oxidative phosphorylation (OXPHOS), which uses the energy generated by mitochondrial oxidation to produce adenosine triphosphate (ATP). This metabolic pathway is highly efficient in releasing energy but it produces reactive oxygen species (ROS) as a byproduct. ROS are involved in normal cell signaling and homeostasis. However, under stress conditions levels may rapidly increase resulting in cell damage, a process known as oxidative stress. Hence, cells using mitochondria as first energy source must regulate ROS levels. Logically, ROS and mitochondria are functionally linked in several ways. First, ROS in the short-term regulate mitochondrial morphology and function via non-transcriptional pathways 1 . Second, ROS lead to Kelch-like ECH-associated protein 1 (KEAP-1) degradation, thereby activating nuclear factor (erythroid-derived 2)-like 2 (NFE2L2 or NRF2) 2, 3 , which regulates expression of mitochondrial genes 4 . In addition, NRF2 controls ROS production by mitochondria 5 and mitochondrial function 6, 7 . NRF2 arguably mediates the strongest anti-oxidant cellular response by binding to anti-oxidant response elements (ARE) in gene promoters and, consequently, regulates oxidative stress 2, 3 . On the other hand, mitochondrial activity induced by acute exercise promotes Ref1/Nrf2 signaling and increases mitochondrial antioxidant activity and capacity in myocardial and skeletal muscle 8, 9 . Remarkably, restraining OXPHOS in vivo in the liver strongly decreases Nrf2 levels OXPHOS generate a NRF2-mediated anti-ROS response 11 . However, how mitochondria transcriptionally signal the genetic program to block the ROS they produce remains unknown.
NRF2 activation depends on its dissociation from the repressor protein KEAP1 and its subsequent translocation into the nucleus 2 . In hematopoietic cells, the MAPK extracellular signal-regulated kinase-5 (ERK5), through the transcription factor MEF2, induces expression of miR-23 that inhibits KEAP-1 mRNA leading to NRF2 activation 11 . Several types of oxidative stress activate ERK5 12 , notably in leukemic cells 11, 13, 14 . In fact, ERK5 is considered a redox MAPK 15 . In endothelial cells, steady laminar blood flow (s-flow) activates ERK5 that induces up-regulation of NRF2-dependent gene expression, although the mechanism is not fully elucidated 16, 17 . Growing evidence indicates that there are alternative pathways leading to de novo production of NRF2 3 . In this context, KEAP-1 inhibition only partially accounts for OXPHOS-induced antioxidant response 11 . Chip-seq experiments performed by the ENCODE consortium have shown that the NRF2 promoter contains MEF2 binding sites 18 . Moreover, predicted networks of transcription factor interactions in skeletal muscle unveil direct regulation of NRF2 by MEF2A 19 and MEF2D binds and activates the Nrf2 promoter 20 . Hence, ERK5 could transcriptionally induce NRF2 expression through MEF2, a transcription factor that mediates some of the metabolic effects of ERK5 11, 13, 14, [21] [22] [23] [24] . In fact, ERK5 regulates the choice of catabolic substrates in hematopoietic cells 11, 13, 14, [21] [22] [23] , suggesting that is a good candidate to mediate the link between OXPHOS and the antioxidant response. We hypothesize that mitochondrial activity triggers the ERK5 pathway that, through MEF2, induces NRF2 expression and NRF2-mediated antioxidant response. We validate this by showing that mitochondrial complex I activity and fumarate accumulation induce the transcriptional expression of ERK5. ERK5 through MEF2 induces NRF2 de novo expression. Therefore, mitochondrial activity is directly linked to the most important antioxidant response in the absence of de novo increase in ROS levels. This implies that eukaryotic cells have evolved a genetic program to prevent oxidative stress directly linked to OXPHOS and not requiring ROS.
Results

OXPHOS-induced de novo expression of NRF2.
We have previously described that leukemic cells performing OXPHOS generated an anti-oxidant response independently of ROS 11 . This response was partially mediated by an ERK5-induced increase in miR-23 that impairs expression of KEAP-1 11 . In parallel experiments, we found that NRF2 mRNA was also increased in three hematopoietic cell lines and in primary cells obtained from a B-cell lymphoma (BCL) patient growing in OXPHOS medium (Fig. 1A) . This glucose-free culture medium has final concentrations of 4 mM glutamine and 10 mM galactose. Glutamine is used to drive mitochondria to utilize OXPHOS and galactose allows cells to synthesize nucleic acids through the pentose phosphate pathway 13, 14, 25, 26 . We called it 'OXPHOS medium' , because it forced leukemic cells to use OXPHOS as primary ATP producer 13, 24, 27 . The PDK1 inhibitor dichloroacetate (DCA), which stimulates OXPHOS in all tested leukemic cells 11, 13, 14, 22, 27, 28 , also increased NRF2 mRNA (Fig. 1A) . Both ways to stimulate OXPHOS also induced NRF2 protein (Fig. 1B) . The effect of DCA on NRF2 mRNA and protein is reproduced in two hepatic cell lines (Supplemental Fig. 1A ) and in a group of primary leukemic cells from 4 patients (Supplemental Fig. 1B ). Of relevance, we observed that in primary human hepatocytes DCA also increased ERK5 and NRF2 mRNA as well as that of the NRF2 targets HO-1 and NQO-1 (Fig. 1C) . In summary OXPHOS induced expression of NRF2 in multiple cell contexts.
OXPHOS induced NRF2 translocation to the nucleus. NRF2 must translocate to the nucleus to activate its target genes and generate the antioxidant response. HuH7 hepatic cells treated with DCA showed NRF2 accumulation in the nucleus ( Fig. 2A) . These results were reproduced in non-adherent Jurkat cells by western blotting (Fig. 2B ) and in the hepatic cell line HepG2C3A (Supplemental Fig. 2A ). We observed a total increase in NRF2 that was more predominant in the nuclear fraction. OXPHOS medium also induced NRF2 translocation to the nucleus in Jurkat cells (Supplemental Fig. 2B ).
OXPHOS induced de novo expression of NRF2 in vivo.
To test if enhanced OXPHOS could exert a similar effect on NRF2 expression in vivo, we engrafted AML primary cells in non-obese diabetic/severe combined immunodeficient (NOD/SCID)-interleukin-2 receptor γ null (NSG) mice, as previously described 27 . Mice with established tumors (day 80 post-graft) were treated with DCA. The treatment was not toxic and did not show any notable effect on mouse survival 27 . Human tumor AML cells gather in mouse spleen and bone marrow, hence we isolated mRNA from these organs. We used human-specific primers to analyze the expression of the selected mRNAs and found an increase in NRF2 mRNA (Fig. 3A) . This increase paralleled that of ERK5 and NQO-1 under similar conditions 11 . DCA also induced mouse Erk5, Nrf2 and Nqo1 mRNA in liver and spleen in a separate experiment in which C57BL/6 wild type mice were treated for different periods of time, 1 to 3 days, with DCA (Fig. 3B) . The effect was first observed in spleen and later in liver tissue. Nrf2 was likely active because we observed an increase in its target gene Nqo-1 (Fig. 3B) . Hence DCA induced NRF2 expression in multiple cell populations in vitro and in vivo.
Increase in ROS levels is not essential for NRF2 expression. The cellular oxidative state can regulate NRF2 expression 2 . Therefore, we investigated whether NRF2 expression is regulated by ROS in our setting. DCA induces ROS production in some hematopoietic cell lines, e.g. OCI-AML3, but not all, e.g. Jurkat 11, 27, 29 . In contrast, both cell lines increased NRF2 expression suggesting that ROS production was not essential for this induction (Fig. 4) . Next, we incubated both cell lines with the antioxidant N-acetyl-cysteine (NAC), which failed to consistently reduce DCA-induced ERK5, NRF2 or NQO-1 mRNA (Fig. 4) , although efficiently blocked DCA-induced ROS increase 11, 29 . We observed similar results in primary leukemic cells from a BCL patient (BCL-P2). DCA does not increase ROS in the hepatic cell line HepG2C3A, but it did in Huh7 29 . However, DCA significantly increased ERK5, NRF2 or NQO-1 mRNA in both cell lines and in the presence of NAC (Supplemental Fig. 3) . These results excluded a major role of ROS in NRF2 expression after DCA treatment. Normally ROS activate NRF2. Unexpectedly in AML cells, there is no relationship between high ROS levels and high nuclear NRF2 30 . Furthermore, the use of NAC, which successfully sequesters endogenous ROS in AML, has no effect on nuclear NRF2 levels 30 . Taken together, this excludes ROS as causing nuclear accumulation of NRF2 in resting human AML cells 30 . ERK5/MEF2 controls NRF2 expression. Next, we investigated the mechanism responsible for mitochondria activity-induced NRF2 expression. Reducing expression of ERK5 with a small hairpin RNA (shERK5) diminished NRF2 mRNA expression in hematopoietic cells under resting conditions (Fig. 5A ). NRF2 protein levels were also reduced after shERK5 transfection (Fig. 5B ). We could not treat shERK5-expressing cells with DCA because they die due to lack of appropriate mitochondrial functions and antioxidant response 11, 13, 14, [21] [22] [23] . Conversely, overexpression of ERK5 increased NRF2 mRNA (Fig. 5A ). Reducing expression of ERK5 in primary human hepatocytes (Fig. 5C ) and hepatic cell lines, HuH7 and HepG2C3A (Supplemental Fig. 1A ,B), with small interference RNA for ERK5 (siERK5) also impaired expression of NRF2 and its target genes NQO-1 and HO-1.
To further study the role of the ERK5/MEF2 pathway in NRF2 expression, we overexpressed several proteins of this pathway. Strong activation of the ERK5 pathway by co-overexpression of a constitutively active mutant of MEK5 (MEK5D), the upstream kinase of ERK5, and ERK5 induced a greater increase in NRF2 mRNA (Supplemental Fig. 4C ). In those experiments, only 30-60% of the cells are effectively transfected. To overcome this issue, we use a luciferase reporter plasmid driven by a DNA fragment of 1.5 kb of the human NRF2 promoter 30 . In this context, cells expressing the reporter plasmid also contain the overexpressed proteins. ERK5 significantly activated the reporter and MEK5D increased this effect (Fig. 5D ). Expression of a dominant negative form of MEF2C (MEF2C-DN) decreased the effect of ERK5 and MEK5D. This DN construct also diminished basal or DCA-stimulated reporter expression. In contrast, MEF2C overexpression increased both basal and DCA-induced activity (Fig. 5D ). DCA, which induced strong activation, did not show a synergistic, but rather an additive, effect with the activating proteins. These results suggested that ERK5 controls NRF2 expression through MEF2. To test this, we transfected a small interference RNA for MEF2 (siMEF2) in the hepatic cell line HepG2C3A (Supplemental Fig. 4D ) and the AML cell line OCI-AML3 (Fig. 5E ). This efficiently decreased MEF2 mRNA and protein 29 and also decreased both basal and DCA-induced NRF2 mRNA (Fig. 5E ).
Mitochondrial complex I activity signals ERK5 expression. The previous experiments had shown that
OXPHOS generates a signal that induces ERK5 expression, which contributes to the NRF2-mediated antioxidant response. We confirmed this in vivo by using a transgenic Tet-Off mouse that express a mutant active form of the ATPase Inhibitory Factor 1 (IF1) in hepatocytes to restrain OXPHOS in the liver 10 . Interestingly Santacatterina et al. describe in the Fig. 8C of their MS that liver Nrf2 levels are lower in mice expressing IF1. We confirmed it by analyzing expression of Nrf2 mRNA (Fig. 6A ). This correlated with lower expression of Erk5 mRNA as compared to wild type mice (Fig. 6A ). This shows that OXPHOS also induces Erk5 mRNA expression in vivo.
We confirmed the essential role of mitochondrial function on ERK5 expression by using fibroblasts derived from patients with strong mitochondrial disorders (Supplemental Table 1 ). ERK5 and NRF2 mRNA were significantly reduced in these patients (Fig. 6B) .
We next focused on the molecular mechanisms underlying our observations. When we inhibited the mitochondrial complex I with metformin, we observed a decrease on ERK5, NRF2 and NQO-1 mRNA and protein expression (Fig. 6C) . Both metformin and DCA induce AMPK activation 27 , however, they blocked and induced ERK5 expression, respectively. This suggested that AMPK and its associated metabolic changes were not involved in ERK5 expression. We confirmed this by reducing the expression of the catalytic subunit of AMPK, AMPKα, with 2 different siRNA that effectively blocked several AMPK-mediated metabolic changes 27 . This did not affect expression of ERK5 or NRF2 mRNA (Supplemental Fig. 5 ). Therefore, AMPK activation was not responsible for generating the antioxidant response in cells performing OXPHOS. Increase in ROS levels is not required for NRF2 expression. OCI-AML and HuH7 cell lines and primary leukemic cells from a BCL patient were treated with 2 mM NAC 1 h before adding DCA (10 mM) for 24 h. mRNA was analyzed as described in Fig. 1 . Experiments were done in triplicate and data represent means ± SD; statistics were performed using One-way ANOVA with post-hoc Tukey test; *p < 0.05, **p < 0.01, ***p < 0.001. Treatments were compared to non-treated cells (control) if not specified in the graph. In Fig. 6C we showed that complex I inhibition decreased ERK5 mRNA. The electron transport chain complex III removes electrons from ubiquinol (QH 2 ) and sequentially transfer them to cytochrome c. The reduction of ubiquinone (Q) to QH 2 could either be due to mitochondrial complex I, which removed electrons from NADH, or mitochondrial complex II, which removed them from succinate and transferred through FAD. Then, we investigated the effect of the complex II inhibitor thenoyltrifluoroacetone (TTFA). This drug strongly induced ERK5 mRNA expression (Fig. 6D) . DCA did not increase TTFA effects suggesting that both shared the same target.
TTFA was slightly toxic (Supplemental Fig. 6A ) and, like metformin, could have off-target effects. Therefore, we used an array of cell lines with impaired activity of the different mitochondrial complexes (Supplemental table 2). ρ0 cells that lack mitochondrial DNA and thus a functional ETC, did not induce ERK5 expression after DCA treatment (Fig. 6E, right lower panel) , in agreement with our previous results showing that mitochondrial activity induced ERK5 expression (Fig. 6A,B 13 . We next used 3 different cell lines in 2 different mitochondrial backgrounds with defects in mitochondrial complex I and observed that DCA treatment did not induce ERK5 expression (Fig. 6E , left panels). In agreement with Fig. 6D , mutation in mitochondrial complex II did not inhibit DCA-induced ERK5 expression (Fig. 6E, top right panel) . Cells with mutations in complex III and V, but not in complex IV, increased ERK5 expression after DCA treatment (Fig. 6E, right panels) . However, complex V mutant show lower basal ERK5 mRNA levels in agreement with in vivo experiments (Fig. 6A) . Mutation in the mitochondrial tRNA Ile in the L929 cell line (mB77), which produces more ROS 31 , did not increase ERK5 mRNA (Fig. 6E, upper right panel) . This supported our results in Fig. 4 showing that de novo ROS production was not involved in ERK5 expression.
Mitochondria adapt the organization of the different complexes and supercomplexes to optimize the use of the available substrates, mainly regulating the proportion of respiratory complex III superassembled with complex I for electron transport. This is needed to avoid competition between FADH 2 -and NADH-derived electrons 31 . DCA, by inhibiting PDK1, activates PDH and the formation of acetyl-CoA from pyruvate. This generates 3 NADH per 1 FADH 2 (through succinate) molecules in the TCA cycle. Other substrates however, generate a different proportion of NADH/FADH 2 electrons and therefore a different demand of CI/CII dependent oxidation. Therefore, while both complexes are always delivering electrons to the ETC simultaneously, the requirement of complex I seems relatively favored by DCA. Complex II, or succinate dehydrogenase (SDH), is also part of the Krebs cycle and catalyzes the conversion of succinate to fumarate. Hence, if complex II is outcompeted by complex I activity, succinate accumulation and fumarate reduction may be induced. Both phenomena are well known in intracellular signaling. Fumarate and succinate, in their acid form, acidify culture media. Hence, we used monomethylsuccinate (MMS) and dimethylfumarate (DMF) to investigate the impact of fumarate and succinate accumulation on ERK5 expression. MMS decreased ERK5 levels (Fig. 7A) . In contrast, DMF increased them (Fig. 7A) . Next, we used metformin to inhibit complex I, forcing the use of complex II, and added MMS to increase complex II activity. When used together, they decreased even further ERK5 expression (Fig. 7B) . This suggested that complex II activity reduced ERK5 expression, probably by inhibiting complex I activity. In summary, whereas succinate probably does not play any role per se on ERK5 expression, fumarate induces its expression. This suggested that DCA, by accumulating fumarate, induces ERK5 mRNA.
Complex I receive electrons from NADH and deliver them to CoQ. Complex II employs FADH as co-factor to deliver electrons from succinate to CoQ.FADH 2 . Therefore, the ratio of NADH/FADH 2 electrons changes with different substrates and the requirement of complex I for NADH oxidation vary according to the NADH/FADH 2 ratio. Oxidative metabolism of one molecule of glucose generates ten NADH and two FADH2, a NADH:FADH2 electron ratio of 5. Fatty acids (FA), e.g. palmitate, generate a ratio of 2 32 . Etomoxir inhibits FA transport into the mitochondria and blocks fatty acid oxidation (FAO), resulting in an increase of the ratio NADH/FADH 2 . Interestingly, etomoxir decreased basal and DCA-induced increase ERK5 mRNA (Fig. 7C) . Therefore, we found no correlation between ERK5 expression and the expected changes in NADH/FADH 2 ratio. Etomoxir and DCA were not toxic to OCI-AML3 cells, although they decreased cell proliferation (Supplemental Fig. 6B ). However when combined they induced cell death suggesting that DCA treatment requires FAO for cell survival as suggested by our previous results 29 . In summary complex I activity, through accumulating fumarate, induces ERK5 expression leading to NRF2-mediated antioxidant response.
Discussion
ROS generation is inherent to the activity of the electron transport chain, with Complex I being considered one of the main sites at which premature electron leakage to oxygen occurs and give rise to superoxide anion 33 . We show here that complex I activity initiates an antioxidant response mediated by ERK5-induced NRF2 expression. It is interesting to note that the main generator of ROS is at the same time responsible of triggering the mechanism to eliminate them. Of relevance, ROS de novo production is not required for this response. The cell "anticipates" ROS formation and activates the pathway to avoid their uncontrolled increase. Once produced, ROS quickly originate biochemical reactions that generate damage to cell structures. Hence, it is on the cell's own benefit to create the antioxidant response when ROS production is going to occur. However, new data are challenging the "only" deleterious view of mitochondrial ROS. For example ROS increase with aging, but increasing mitochondrial ROS production specifically through the respiratory complex I reverse electron transport (RET) extends Drosophila lifespan 34 . and β-galactosidase activities. The graphic represents the relative luciferase units (RLU). (E) OCI-AML3 cells were transfected with siRNA for MEF2A and C and 24 h later treated with 10 mM DCA for 36 h. NRF2 mRNA and NRF2 protein were analyzed as in in (A) and (B) respectively. Experiments were done in triplicate. The data represent means ± SD; statistics were performed using student t-test (C) or One-way ANOVA with posthoc Tukey test (A,D and E); *p < 0.05, **p < 0.01, ***p < 0.001. Treatments were compared to empty vector transfected cells (control) if not specified in the graph. Table 1 ). (C) Different hematopoietic cell lines were incubated for 24 h with 5 mM metformin. mRNA expression was quantified by qPCR and represented as the % of mRNA compared non-treated cells. ERK5 and NRF2 protein expression was analyzed in these cell lines by western blotting (lower panel). (D) Jurkat and OCI-AML3 cells were treated with 10 mM DCA and 300 µM TTFA for 24 h. NRF2 mRNA expression was quantified by qPCR and represented as the % of mRNA compared to control cells. (E) Different cell lines described in Supplemental Table 2 were treated with 20 mM DCA during 24 hours. ERK5 mRNA was quantified by qPCR and represented as the % of mRNA compared to non-mutant control cells. Experiments were done in triplicate and data represent means ± SD; statistics were performed using student t-test (A-C) or One-way ANOVA with post-hoc Tukey test (D and E); *p < 0.05, **p < 0.01, ***p < 0.001; § p < 0.05, § § p < 0.01 compare to the respective control cell lines. Treatments were compared to non-treated cells (control) if not specified in the graph. We show that mitochondrial complex I activity is required for ERK5-induced NRF2 expression. We have examined several possibilities that could account for our observation. DCA inhibits glycolysis and increases FAO as suggested by the high toxicity of the combined etomoxir plus DCA treatment ((Supplemental Fig. 6 ) and 29 ). Then, this switch would change NADH:FADH2 electron ratio. When electron flux from FAD overwhelms the oxidation capacity of CoQFAD, CI is degraded, releasing CIII from CI-containing complexes to receive FAD-derived electrons 35 . The increased electron flux through FAD could saturate the oxidation capacity of the dedicated coenzyme Q (CoQ) pool and result in the generation of ROS 36 . However, in our experiments ROS do not mediate OXPHOS-induced ERK5 expression (Figs 4 and 6) . Moreover, etomoxir decreases basal ERK5 expression but it does not block DCA-induced increase. Finally, if FAO is inducing ERK5 expression, complex II inhibition should decrease it, but we found an increase with TTFA and basically no effect by genetic approaches. This suggests that another mechanism is responsible for triggering ERK5 expression.
In non-transformed cells inhibition of OXPHOS by IF1 induces AMPK activation 10 , which could lead to ERK5 activation 37 . DCA also induces AMPK 27 . However, our pharmacological (metformin, Fig. 6C ) and genetic (siRNA, Supplemental Fig. 5 ) approaches suggest that AMPK is not involved on ERK5 expression during OXPHOS.
Strong mitochondrial complex I activity could decrease electron transport through complex II and the subsequent accumulation of succinate or reduced fumarate be responsible for ERK5 expression. Our results using TTFA or genetically-modified cells support this conclusion (Fig. 6) . However, MMS fails to induce ERK5 even if complex I was blocked by metformin (Fig. 7) . In contrast, we found that DMF induced ERK5 (Fig. 7) . Interestingly, DMF induces Nrf2 expression through a PD98059-sensitive pathway 38 . Although this MAPKK inhibitor was initially described as a specific MEK1 inhibitor, it also inhibits the ERK5 upstream kinase MEK5 39 . Therefore, fumarate indeed mediates ERK5 expression. Accumulated fumarate can covalently modify cysteine residues of proteins, in an uncatalyzed process termed succination, modifying cellular signaling 40 . Succination occurs on KEAP1 41 and results in constitutive NRF2 activation and increased expression of its target genes 41 . Therefore, fumarate induces the NRF2-mediated antioxidant response by directly affecting KEAP-1 41 and by inducing de novo NRF2 expression (our results).
An alternative is that succinate promotes CII activity and induces RET thereby decreasing mitochondrial membrane potential. In reverse, fumarate blocks CII thereby increasing complex I activity and this could trigger ERK5 expression.
Although it is well-established that ROS induce NRF2 activation 2 , recent data support that alternative pathways independent of ROS are also operative. For example, OXPHOS decreases KEAP-1 expression independently of ROS 11 and NRF2 expression in AML depends on NF-κB but not on ROS 30 . Interestingly, ERK5 activates NF-κB in leukemic cells 42 . Hence, ERK5 could handle the NRF2-mediated antioxidant response by at least 3 mechanisms independently of de novo ROS generation: i) direct transcription through MEF2 (the results presented here); ii) direct transcription through NF-κB 30, 42 ; iii) upregulation of miR-23 and downregulation of KEAP1 mRNA 11 . This emphasizes the central role of ERK5 in the antioxidant response [11] [12] [13] [14] [15] [16] [17] . Transcriptome analysis shows that the ERK5 pathway regulates in normoxia several genes involved in metabolic remodeling, including some controlled by hypoxia inducible factor-1α (HIF-1α under hypoxia 13, 43 . Also, like HIF-1α, ERK5 is degraded by a process depending on the tumor suppressor von Hippel-Lindau (VHL), through a prolyl hydroxylation-dependent mechanism 44 . Hence, mitochondrial complex I activity through fumarate accumulation could also protect ERK5 from VHL-induced degradation. This is based on the fact that succinate and fumarate (and succinate) outcompete α-ketoglutarate, an essential co-factor of prolyl hydroxylase domain enzymes 45 . How ERK5 induces NRF2 mRNA expression is not totally elucidated. ERK5 directly phosphorylates MEF2A, C and D at different serines and threonines 46, 47 . It activates MEF2A and D by direct interaction because ERK5 serves as a MEF2 coactivator through its signal-dependent direct association with the MEF2 MADS domain; although, at least, MEF2A-dependent transcription requires ERK5 kinase activity 48, 49 . Finally, forcing cells to produce energy through OXPHOS also affects cell viability and proliferation independently of ROS. This is rather related to energy depletion. In this sense OXPHOS requires mitochondrial function and DCA induces cell death in ρ0 cells, while in other cells it just inhibits growth 11, 23, 50 . In summary forcing OXPHOS in vitro is cytostatic in "normal" tumor cells and cytotoxic in cells with major mitochondrial dysfunctions.
Experimental Procedures
Ethical statement. Experimental procedures were conducted according to the European guidelines for animal welfare (2010/63/EU). Protocols were approved by the Animal Care and Use Committee "LanguedocRoussillon" (approval number: CEEA-LR-12163). The use of human specimens for scientific purposes was approved by the French National Ethics Committee. All methods were carried out in accordance with the approved guidelines and regulations of this committee. Written informed consent was obtained from each patient prior to surgery.
Reagents and antibodies. DCA was from Santa Cruz Technologies. Galactose and glutamine were from GIBCO. RIPA buffer to prepare protein extracts was from Euromedex. The complete protease inhibitor cocktail (Complete EDTA-free) and the phosphatase inhibitor cocktail (PhosSTOP) were from Roche. H 2 O 2 , DMF and MMS were from Sigma. ERK5 and NRF2 antibodies were from Cell Signaling Technology and Santa Cruz respectively. The antibody against β-Actin and HRP-labeled secondary antibodies were from Sigma.
In vivo mouse experiments. In vivo experiments were carried out using 6 to 8 weeks/old male NSG mice.
Mice were bred and housed in pathogen-free conditions in the animal facility of the European Institute of OncologyItalian Foundation for Cancer Research (FIRC), Institute of Molecular Oncology (Milan, Italy). For engraftment of human cells, 1 million AML cells were injected intravenously (i.v.) through the lateral tail vein in non-irradiated mice. NSG mice with established human AML tumors (day 80 post-graft) were treated with DCA (50 mg/kg, 1 dose/ day by gavage, starting at day 1 for 16 consecutive days). Human tumor AML cells gather in mouse spleen and bone marrow, hence we isolated mRNA from these organs. We used human-specific primers to visualize expression of human mRNA. In a different experiment B6 wild type mice were treated with a daily single dose of DCA (50 mg/kg/ day) intraperitoneally and mouse mRNA was analyzed in spleen and liver after different times.
hIF1 Transgenic mice. The samples from transgenic mice containing the mutant H49K version of hIF1 have been described 10 . mRNA was analyzed in liver of these mice. Human liver samples and preparation of primary human hepatocytes (PHHs) cultures. PHHs were isolated as described previously 51 from donor organs unsuitable for transplantation or from liver resections performed in adult patients for medical reasons unrelated to our research program. Liver samples were obtained from the Biological Resource Center of Montpellier University Hospital (CRB-CHUM; http://www. chu-montpellier.fr; Biobank ID: BB-0033-00031) and this study benefitted from the expertise of Dr Jeanne Ramos (hepatogastroenterology sample collection) and Prof Sylvain Lehmann (CRB-CHUM manager). The procedure was approved by the French Ethics Committee and written or oral consent was obtained from the patients or their families.
Human hepatocytes isolation and culture were performed as described previously 51 . Briefly, after liver perfusion, hepatocytes were counted and cell viability was assessed by trypan blue exclusion test. A suspension of 1 × 10 6 cells/mL per well was added in 12-well plates pre-coated with type I collagen (Beckton Dickinson) and cells were allowed to attach for 12 h. Then, the supernatant containing dead cells and debris was removed and replaced with 1 mL of serum-free long-term culture medium (Lanford medium, LNF). The number of confluent attached cells was estimated at ~1. Plasmids. The luciferase reported plasmid driven by a DNA fragment of 1.5 kb of the human NRF2 promoter was a kind gift from Stuart Rushworth 30 . The expression vectors for ERK5, the pSUPER expression vector for GFP alone or GFP plus shERK5 and the pSiren-retroQ-puro (BD Biosciences) retroviral vectors for shERK5 and control have been previously described 52 . Control, MEF2A and C and ERK5 siRNA were ON-TARGETplus SMARTpools (mixture of 4 siRNA) from Dharmacon.
Transient transfection.
Jurkat cells in logarithmic growth phase were transfected with the indicated amounts of plasmid by electroporation 42, 53 . In each experiment, cells were transfected with the same total amount of DNA by supplementing with empty vector. Cells were incubated for 10 min at RT with the DNA mix and elec- Reporter assay. In all experiments, Jurkat cells were transfected with β-galactosidase reporter plasmid 42, 53 . The transfected cells were harvested after 2 days and centrifuged at 1000 g for 5 min. The cell pellet was suspended in 1 ml cold PBS and transferred to 1.5 ml Eppendorf tube for washing. Cells were lysed with 100 μl luciferase lysis buffer (Promega) and incubated at room temperature for 10 min. The lysates were centrifuged and luciferase assays (40 µl) performed according to the manufacturer's instructions (Promega, Charbonnières, France) using a Berthold luminometer. For β-Galactosidase assays, 40 µl of lysates were added to 200 µl of β-Galactosidase assay buffer (50 mM phosphate buffer pH 7.4; ONPG 200 µg; 1 mM MgCl2; 50 mM β-Mercaptoethanol) and the absorbance measured at 405 nm. The results were expressed as luciferase units normalized to the corresponding β-galactosidase activity. The expression level of the transfected proteins was routinely control by immunoblot analysis. 
RT-PCR.
Total RNA was extracted using NucleoSpin RNA isolation columns (Macherey-Nagel), reverse transcription was carried out using iScript ™ cDNA Synthesis Kit (Biorad). Quantitative PCR was performed with KAPA SYBR Green qPCR SuperMix (Cliniscience) and a CFX Connect ™ Real-Time qPCR machine (Biorad) with ERK5, NRF2, NQO1, HO-1 and actin primers. Supplemental Table 3 shows all primers used in this study. All samples were normalized to β-actin mRNA levels. Results are expressed relative to control values arbitrarily set at 100 27 .
Immunoblotting. Protein analysis by immunoblotting was performed essentially as previously described 27 . Briefly, samples were collected, washed out with PBS and lysed with RIPA buffer. Protein concentration was determined by BCA assay (Pierce) before electrophoresis in 4-15% TGX gels (BioRad) and equal amount of protein was loaded in each well. Protein transfer was performed in TransTurbo system (BioRad) in PVDF membranes. After blocking for 1 h with 5% non-fat milk, membranes were incubated overnight at 4 °C in agitation with primary antibodies, washed three times with PBS-Tween 0,1% and incubated with the appropriate HRP-labeled secondary antibody for 1 h. Membranes were washed out three times with PBS-Tween 0,1% and developed with Substrat HRP Immobilon Western (Millipore). Band quantification was performed using the "ImageLab" software from BioRad and represented as the ratio between the protein of interest and a control protein i.e. actin. The value of 1 is arbitrarily given to control cells. One blot representative of several experiments is shown.
Statistical analysis.
The statistical analysis of the difference between means of paired samples was performed using the paired t test. Multiple comparisons were performed using One-way ANOVA with post-hoc Tukey HSD test. The results are given as the confidence interval (*p < 0.05, **p < 0.01, ***p < 0.005). All the experiments described in the figures with a quantitative analysis have been performed at least three times in duplicate. Other experiments were performed three times with similar results. We used actin as a loading control and the histograms represent the ratio (value of protein of interest)/(value of actin).
